Zheng Yuansheng, Huang Yiwei, Bian Yunyi, Du Yajing, Lu Tao, Sui Qihai, Li Ming, Chen Zhencong, Zhan Cheng, Xi Junjie, Jiang Wei, Wang Qun
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Center for Tumor Diagnosis and Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Ann Transl Med. 2021 Feb;9(3):215. doi: 10.21037/atm-20-3957.
Lung cancer is the leading cause of cancer-related death, and countries all over the world have given considerable support to lung cancer research. However, analysis on the status of funding in the field of lung cancer is still lacking.
We visited the National Natural Science Foundation of China (NSFC) and National Institutes of Health (NIH) official websites to gather lung cancer research information between 2008 and 2020. RSTCM6 software was used to extract the keywords of funded projects which were then imported into CiteSpace software for visual analysis of word frequency.
A total of 1,745 and 5,939 search results were finally obtained from the NSFC and NIH websites, respectively. The amount of NSFC funding for projects in the field of lung cancer increased steadily from 2008 to 2012, while the NIH funding for lung cancer was significantly higher in even years than in odd years between 2008 to 2018. The Shanghai Jiaotong University, Sun Yat-sen University, and Guangzhou Medical University were the top three research institutions that had received the most projects funded by the NSFC. Apoptosis, proliferation, invasion, metabolism, the pathogenesis of lung cancer, cell signal transduction, epithelial-mesenchymal transformation (EMT), and immune-related research were the most frequently funded research areas by the NSFC. Biomarkers, targeted therapy, signal pathway, genomics, and immune-related research were funded most the most frequently funded research areas by the NIH. Both the NIH and NSFC funding for lung cancer immune-related research has increased in recent years.
NIH funding in the United States is decreasing year by year, whereas NSFC funding is increasing in China. There are some differences in research focus in lung cancer research funding between China and the United States. However, both countries have increased the support for immune-related research in recent years.
肺癌是癌症相关死亡的主要原因,世界各国都对肺癌研究给予了相当大的支持。然而,目前仍缺乏对肺癌领域资金资助状况的分析。
我们访问了中国国家自然科学基金委员会(NSFC)和美国国立卫生研究院(NIH)的官方网站,收集2008年至2020年间的肺癌研究信息。使用RSTCM6软件提取资助项目的关键词,然后将其导入CiteSpace软件进行词频可视化分析。
最终分别从NSFC和NIH网站获得了1745条和5939条搜索结果。2008年至2012年,NSFC对肺癌领域项目的资助金额稳步增加,而2008年至2018年期间,NIH对肺癌的资助在偶数年份明显高于奇数年份。上海交通大学、中山大学和广州医科大学是获得NSFC资助项目最多的前三所研究机构。细胞凋亡、增殖、侵袭、代谢、肺癌发病机制、细胞信号转导、上皮-间质转化(EMT)和免疫相关研究是NSFC资助最多的研究领域。生物标志物、靶向治疗、信号通路、基因组学和免疫相关研究是NIH资助最多的研究领域。近年来,NIH和NSFC对肺癌免疫相关研究的资助都有所增加。
美国NIH的资助逐年减少,而中国NSFC的资助在增加。中美两国在肺癌研究资助的研究重点上存在一些差异。然而,近年来两国都增加了对免疫相关研究的支持。